Enhancing the Antitumor Immunity of T Cells by Engineering the Lipid-Regulatory Site of the TCR/CD3 Complex

• Published in: Cancer immunology research 2023-01, Vol.11 (1), p.93-108
• Main Authors: Liang, Wenhua, Yi, Ruirong, Wang, Weifang, Shi, Yiwei, Zhang, Jiqin, Xu, Xiang, Wang, Qingcan, Liu, Mingyao, Wang, Feng
• Format: Article
• Language: English
• Subjects: Animals; Calcium - metabolism; CD3 Complex - genetics; Humans; Lipids - analysis; Mice; Phosphorylation; Receptor-CD3 Complex, Antigen, T-Cell - chemistry; Receptor-CD3 Complex, Antigen, T-Cell - genetics; Receptors, Antigen, T-Cell - genetics; Receptors, Antigen, T-Cell - metabolism; T-Lymphocytes
• ISSN: 2326-6066; 2326-6074
• DOI: 10.1158/2326-6066.CIR-21-1118

The engagement of the T-cell receptor (TCR) by a specific peptide-MHC ligand initiates transmembrane signaling to induce T-cell activation, a key step in most adaptive immune responses. Previous studies have indicated that TCR signaling is tightly regulated by cholesterol and its sulfate metabolite, cholesterol sulfate (CS), on the membrane. Here, we report a novel mechanism by which CS modulates TCR signaling through a conformational change of CD3 subunits. We found that the negatively charged CS interacted with the positively charged cytoplasmic domain of CD3ε (CD3εCD) to enhance its binding to the cell membrane and induce a stable secondary structure. This secondary structure suppressed the release of CD3εCD from the membrane in the presence of Ca2+, which in turn inhibited TCR phosphorylation and signaling. When a point mutation (I/A) was introduced to the intracellular immunoreceptor tyrosine-based activation motifs (YxxI-x6-8-YxxL) of CD3ε subunit, it reduced the stability of the secondary structure and regained sensitivity to Ca2+, which abolished CS-mediated inhibition and enhanced the signaling of the TCR complex. Notably, the I/A mutation could be applied to both murine and human TCR-T cell therapy to improve the antitumor efficacy. Our study reveals insights into the regulatory mechanism of TCR signaling and provides a strategy to functionally engineer the TCR/CD3 complex for T cell-based cancer immunotherapy.